John Alexander Kelly Buys 2,113 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Posted by Simon Gomez on Jan 3rd, 2025

Precision BioSciences, Inc. (NASDAQ:DTIL – Get Free Report) CFO John Alexander Kelly bought 2,113 shares of the stock in a transaction on Friday, December 27th. The stock was acquired at an average price of $4.75 per share, with a total value of $10,036.75. Following the completion of the acquisition, the chief financial officer now owns 40,186 shares of the company’s stock, valued at $190,883.50. This represents a 5.55 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Precision BioSciences Price Performance

Precision BioSciences stock opened at $4.69 on Friday. The stock has a market capitalization of $35.98 million, a price-to-earnings ratio of 78.18 and a beta of 1.41. Precision BioSciences, Inc. has a 52-week low of $3.61 and a 52-week high of $19.43. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22. The stock’s 50 day moving average price is $6.52 and its two-hundred day moving average price is $8.48.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC raised its stake in Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) by 10.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 702,069 shares of the company’s stock after purchasing an additional 68,943 shares during the period. Janus Henderson Group PLC owned 9.15% of Precision BioSciences worth $6,322,000 as of its most recent SEC filing. Institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

(Get Free Report)

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.